Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Ascent Resources ask shareholders for ability to raise funds


Hemogenyx Share Price (HEMO)



Share Price Information for Hemogenyx (HEMO)


Share Price: 2.70Bid: 2.50Ask: 2.90Change: 0.00 (0.00%)No Movement on Hemogenyx
Spread: 0.40Spread as %: 16.00%Open: 2.70High: 2.70Low: 2.70Yesterday’s Close: 2.70

Hemogenyx Pharmaceuticals Plc Ord Gbp0.01

Hemogenyx is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
2.70
Share Price SpacerBid
2.50
Share Price SpacerAsk
2.90
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
0
Share Price SpacerOpen
2.70
Share Price SpacerHigh
2.70
Share Price SpacerLow
2.70
Share Price SpacerClose
2.70
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 360.18m £9.72m 30,000

52 Week High 6.75 52 Week High Date 26-FEB-2018
52 Week Low 2.00 52 Week Low Date 22-FEB-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -3.000 -0.90 0.00 0.00


London South East Users info for Hemogenyx




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

13-Nov-18
14:20:09
2.90
150,000
Buy* 
2.50
2.90
4,350
Trade Type:
Ordinary

13-Nov-18
14:19:59
2.835
150,000
Buy* 
2.50
2.90
4,253
Trade Type:
Ordinary

13-Nov-18
13:35:42
2.6413
22,306
Sell* 
2.50
2.90
589.17
Trade Type:
Ordinary




View more Hemogenyx trades >>

Directors Deals for Hemogenyx (HEMO)
Trade DateActionNotifierPriceCurrencyAmountHolding
05-Feb-18Buy
Trade Notifier Information for Hemogenyx Pharmaceuticals
Vladislav Sandler Ph.D. held the position of CEO at Hemogenyx Pharmaceuticals at the time of this trade.
 Vladislav Sandler Ph.D.
2.37GBX26,80040478010
06-Oct-17Buy
Trade Notifier Information for Hemogenyx Pharmaceuticals
Adrian Beeston held the position of Non-Executive Director at Hemogenyx Pharmaceuticals at the time of this trade.
 Adrian Beeston
3.1GBX10,0005424286
06-Oct-17Buy
Trade Notifier Information for Hemogenyx Pharmaceuticals
Peter Redmond held the position of Non-Executive Director at Hemogenyx Pharmaceuticals at the time of this trade.
 Peter Redmond
3.14GBX155,0005040714
View more Hemogenyx directors dealings >>


Shukan
Posts: 2,080
Opinion:Strong Buy
Price:2.70
RE: Hemo
Tue 14:10
Way above N4P in terms of who is on board and any potential outcome from such collaboration's
FeverClucker
Posts: 653
Opinion:Strong Buy
Price:2.85
RE: Hemo
Mon 18:06
Think this could be next N4P re SP
Tillywhiz
Posts: 27
Premium Chat Member
Opinion:No Opinion
Price:2.70
Hemo
Mon 14:06
A slice of blue in plenty of red
Shukan
Posts: 2,080
Opinion:Strong Buy
Price:2.50
CEO Vered Caplan
7 Nov '18
Quickdraw18
Posts: 8
Opinion:No Opinion
Price:2.50
Mice
6 Nov '18
Any thoughts on revenue we can expect the receive from the mice over next 2>3 yrs?

Based on 1st deal being worth up to $250k for 6 months. I'll value each deal at $500k per annum with 4 agreements in the bag currently.

Seems feasible Hemo could be making $5m>$10m a year or two. Plus if successful i expect contact values to increase.

PS making first buy of thousand £ on Friday. Aiming to time extension of first mouse deal, which believe will validate CDX internal testing. Would also be good to get in before the manufacturing ramp up and hopeful commencement of phase 1 testing.
View more share chat for Hemogenyx (HEMO) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.